| Literature DB >> 30128143 |
Abstract
Background: Aerobactin is a critical factor for the hypervirulent Klebsiella pneumoniae (hvKp), but data for the aerobactin-positive genotype of hvKp in elderly persons with ventilator-associated pneumonia (VAP) is limited. The purpose of this study is to understand the risk factors and characteristics of the hvKp genotype for elderly patients with VAP.Entities:
Keywords: Aerobactin; ESBL-hvKp; Hypervirulent; Klebsiella pneumoniae; Risk factor; Ventilator-associated pneumonia
Mesh:
Substances:
Year: 2018 PMID: 30128143 PMCID: PMC6091109 DOI: 10.1186/s13756-018-0371-8
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Primers
| Name | sequence |
|---|---|
|
| |
| Forward | 5-ACTGGGCTACCTCTGCTTCA-3 |
| Reverse | 5-CTTGCATGAGCCATCTTTCA-3 |
|
| |
| Forward | 5-CTTTATGTGCAATAAG-GATGTT-3 |
| Reverse | 5-CCTCCTGGAGAGTAAGCATT-3 |
|
| |
| Forward | 5-GGTGCTCTTTACATCATTGC-3 |
| Reverse | 5-GCAATGGCCATTTGCGTTAG-3 |
|
| |
| Forward | 5-GCATAGGCGGATACGAACAT-3 |
| Reverse | 5-CACAGGGCAATTGCTTACCT-3 |
|
| |
| Forward | 5-GTAGGTATTGCAAGCCATGC-3 |
| Reverse | 5-GCCCAGGTTAATGAATCCGT-3 |
|
| |
| Forward | 5-GGAGCCATTTGAATTCGGTG-3 |
| Reverse | 5-TCCCTAGCACTGGCTTAAGT-3 |
|
| |
| Forward | 5-GCCACCTCTAAGCATATAGC-3 |
| Reverse | 5-CGCACCAGTAATTCCAACAG-3 |
|
| |
| Forward | 5-CCGATTCGGTCAACTAGCTT-3 |
| Reverse | 5-GCACCTCTATGAACTTTCAG-3 |
|
| |
| Forward | 5-CATTAGCTCAGTGGTTGGCT-3 |
| Reverse | 5-GCTTGACAAACACCATAGCAG-3 |
|
| |
| Forward | 5-CGACAAATCTCTCCTGACGA-3 |
| Reverse | 5-CGCGACAAACATAACACTCG-3 |
|
| |
| Forward | 5-GGCGAAATGGCWGAGAACCA-3 |
| Reverse | 5-GAGTCTTCGAAGTTGTAACC-3 |
|
| |
| Forward | 5-TGAAATATGACTCCACTCACGG-3 |
| Reverse | 5-CTTCAGAAGCGGCTTTGATGGCTT-3 |
|
| |
| Forward | 5-TGAAATATGACTCCACTCACGG-3 |
| Reverse | 5-CTTCAGAAGCGGCTTTGATGGCTT-3 |
|
| |
| Forward | 5-GAGAAAAACCTGCCTGTACTGCTGGC-3 |
| Reverse | 5-CGCGCCACGCTTTATAGCGGTTAAT-3 |
|
| |
| Forward | 5-ACCTACCGCAACACCGACTTCTTCGG-3 |
| Reverse | 5-TGATCAGAACTGGTAGGTGAT-3 |
|
| |
| Forward | 5-CTCGCTGCTGGACTATATTCG-3 |
| Reverse | 5-CGCTTTCAGCTCAAGAACTTC-3 |
|
| |
| Forward | 5-CTTTATACCTCGGTACATCAGGTT-3 |
| Reverse | 5-ATTCGCCGGCTGRGCRGAGAG-3 |
Clinical features of patients with VAP due to hvKp
| Characteristic | HvKp(34) | cKp(39) | |
|---|---|---|---|
| Basic demographics | |||
| Age | 83.06 ± 8.55 | 86.62 ± .87 | 0.068 |
| Male | 31 (91.2%) | 35 (89.7%) | 1.000 |
| Underlying diseases | |||
| Pulmonary disease | 31 (91.2%) | 32 (82.1%) | 0.321 |
| Diabetes | 19 (55.9%) | 18 (46.2%) | 0.407 |
| Cardiovascular disease | 12 (35.3%) | 17 (43.6%) | 0.470 |
| Cerebrovascular disease | 11 (32.4%) | 15 (38.5%) | 0.587 |
| Cancer |
|
|
|
| Surgery within 1 mo |
|
|
|
| Digestive disease |
|
|
|
| Infection type | |||
| Sepsis | 30 (88.2%) | 37 (94.9%) | 0.408 |
| Septic shock |
|
|
|
| Host responsibility | |||
| WBC | 12.57 ± 4.47 | 11.68 ± 4.36 | 0.397 |
| NEU% | 78.99 ± 9.54 | 77.13 ± 7.14 | 0.344 |
| Nutrition status | |||
| TP | 63.38 ± 6.34 | 61.88 ± 6.02 | 0.304 |
| ALB | 33.33 ± 3.75 | 32.51 ± 3.39 | 0.326 |
| SOFA score |
|
|
|
| Infection occurred in ICU | 11 (32.4%) | 10 (25.6%) | 0.527 |
| Mortality in 30 days | 14 (41.2%) | 14 (35.9%) | 0.644 |
TP total protein, ALB albumin, WBC white blood cell count, NEU% neutrophils percentage
Microbiological features of patients with VAP due to hvKp
| Characteristic | HvKp(34) | cKp(39) | |
|---|---|---|---|
| K serotype | |||
| K1 |
|
|
|
| | 7 (2.9%) | 2 (5.1%) | 0.073 |
| | 2 (5.9%) | 0 (0%) | 0.213 |
| | 2 (5.9%) | 2 (5.1%) | 1.000 |
| | 3 (8.8%) | 0 (0%) | 0.096 |
| | 4 (11.8%) | 3 (7.7%) | 0.849 |
| rmpA |
|
|
|
| rmpA2 |
|
|
|
| magA |
|
|
|
| Hypermucoviscosity |
|
|
|
Antibiotics resistance: hvKp vs cKp
| Antibiotic agent | HvKp(34) | cKp(39) | |
|---|---|---|---|
| MDR |
|
|
|
| ESBLs |
|
|
|
| Ampicillin | 34 (100%) | 39 (100%) | NA |
| Amikacin | 6 (17.6%) | 12 (30.8%) | 0.194 |
| Gentamicin |
|
|
|
| Ampicillin/Sulbactam |
|
|
|
| Aztreonam |
|
|
|
| Cefazolin |
|
|
|
| Cefotetan |
|
|
|
| Cefepime | 9 (26.5%) | 18 (46.2%) | 0.082 |
| Ceftriaxone | 13 (38.2%) | 23 (59.0%) | 0.077 |
| Ceftazidime |
|
|
|
| Ciprofloxacin | 10 (29.4%) | 20 (51.3%) | 0.058 |
| Levofloxacin | 9 (26.5%) | 19 (48.7%) | 0.051 |
| Trimethoprim/Sulfamethoxazole |
|
|
|
| Piperacillin/Tazobactam |
|
|
|
| Imipenem | 8 (23.5%) | 10(25.6%) | 0.835 |
| Meropenem | 9 (26.5%) | 10(25.6%) | 0.936 |
| Tobramycin |
|
|
|
Risk factor for hvKp vs cKp
| Variable | Univariate OR (95% CI) | Multivariate OR (95% CI) | ||
|---|---|---|---|---|
| Infection occurred in ICU | 1.387 (0.502–3.832) | 0.528 | ||
| Male | 1.181 (0.245–5.694) | 0.836 | ||
| Pulmonary diseases | 2.260 (0.536–9.539) | 0.267 | ||
| Diabetes | 1.478 (0.586–3.725) | 0.408 | ||
| Cardiovascular disease | 0.706 (0.274–1.818) | 0.471 | ||
| Cerebrovascular disease | 0.765 (0.291–2.010) | 0.587 | ||
| Cancer |
|
|
|
|
| Surgery within 1 mo |
|
| ||
| Digestive diseases |
|
| 3.713 (0.970–14.212) | 0.055 |
Features of patients with prevalent hvKp(n ≥ 3)
| ST2906(3) | ST37(3) | ST17(4) | ST412(5) | ST23(15) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| K serotype | ||||||||||
| | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 9 | 0 |
| | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 |
| | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 2 | 2 | 2 | 0 | 10 | 0 |
|
| 0 | 0 | 1 | 0 | 2 | 2 | 2 | 1 | 9 | 0 |
|
| 0 | 0 | 2 | 0 | 2 | 2 | 2 | 1 | 9 | 1 |
| Hmv | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 1 | 9 | 0 |
| hvKp (aerobactin) | 0 | 1 | 0 | 0 | 2 | 2 | 2 | 1 | 10 | 1 |
| Sepsis Shock | 0 | 3 | 0 | 1 | 2 | 1 | 0 | 1 | 8 | 1 |
| Died in 30 Days | 0 | 3 | 2 | 1 | 2 | 0 | 0 | 0 | 8 | 1 |
Hmv hypermucoviscosity, a and b different hospital
Fig. 1Neighbour-joining dendrogram of concatenated sequences of seven housekeeping genes from the MLST database for prevalent STs in our study and the common STs in the world. (Black solid box represents death in our study)